Caspofungin
- Generic Name
- Caspofungin
- Brand Names
- Cancidas, Cancidas (previously Caspofungin MSD)
- Drug Type
- Small Molecule
- Chemical Formula
- C52H88N10O15
- CAS Number
- 162808-62-0
- Unique Ingredient Identifier
- F0XDI6ZL63
- Background
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
- Indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
- Associated Conditions
- Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections
- Associated Therapies
- -
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
- Conditions
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 450
- Registration Number
- NCT05421858
- Locations
- 🇺🇸
Washington University School of Medicine, Infectious Diseases Clinical Research Unit, Saint Louis, Missouri, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Houston Methodist Hospital - Texas Medical Center, Houston, Texas, United States
PK/PD of Caspofungin in Children Severe Infection
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04961593
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
- Conditions
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Bin Du
- Target Recruit Count
- 122
- Registration Number
- NCT03978559
- Locations
- 🇨🇳
MICU of Peking Union Medical College, Beijing, China
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Cttq
- Target Recruit Count
- 32
- Registration Number
- NCT03857399
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Tongji Hospital of Shanghai, Shanghai, Shanghai, China
🇨🇳Affiliated Concord Hospital of Fujian Medical University, Fuzhou, Fujian, China
Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Careggi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03798600
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT03667690
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
🇪🇸Hospital Clinic of Barcelona, Barcelona, Spain
🇮🇹University Polyclinic Foundation Agostino Gemelli - IRCCS, Rome, Italy
Pharmacokinetics of Caspofungin
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 33
- Registration Number
- NCT03399032
- Locations
- 🇵🇱
II Department of Anesthesia and Intensive Care, Medical University of Lublin, Lublin, Poland
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT02895529
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- F2G Biotech GmbH
- Registration Number
- NCT02856178
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT02734862
- Locations
- 🇪🇸
University Hospital La Paz, Madrid, Spain
🇧🇪UCL Saint-LUC, Brussels, Belgium
🇺🇸Virginia Tech, Carillion School of Medicine, Roanoke, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.